Short Communication

Journal of Neural Transmission

, Volume 106, Issue 9, pp 925-929

An overnight switch to ropinirole therapy in patients with Parkinson's disease

  • M. CanesiAffiliated withParkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • , A. AntoniniAffiliated withParkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • , C. B. MarianiAffiliated withParkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • , S. TeseiAffiliated withParkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • , A. L. ZecchinelliAffiliated withParkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • , M. BarichellaAffiliated withParkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy
  • , G. PezzoliAffiliated withParkinson Institute Milan, Istituti Clinici di Perfezionamento, Milan, Italy

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Summary.

Patients with Parkinson's disease (n = 68) switched from per-golide or bromocriptine to ropinirole overnight (dose equivalence ratios – 1 : 6 and 10 : 6, respectively). The activities of daily living score for the Unified Parkinson's Disease Rating Scale (UPDRS) was significantly improved 4 weeks after the bromocriptine–ropinirole switch. All other UPDRS scores, including that for the side-effect component, were not significantly different after either switch. Overnight switching may be a safe therapeutic approach that may reduce hospitalisation and related socio-economic costs.

Keywords: Ropinirole pergolide bromocriptine Parkinson's disease.